Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR Jr, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Hegde A, et al. Among authors: heymach j. ESMO Open. 2020 Oct;5(5):e000799. doi: 10.1136/esmoopen-2020-000799. ESMO Open. 2020. PMID: 33097651 Free PMC article. Clinical Trial.
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Ihle NT, et al. Among authors: heymach jv. J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13. J Natl Cancer Inst. 2012. PMID: 22247021 Free PMC article.
The BATTLE trial: personalizing therapy for lung cancer.
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. Kim ES, et al. Among authors: heymach jv. Cancer Discov. 2011 Jun;1(1):44-53. doi: 10.1158/2159-8274.CD-10-0010. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22586319 Free PMC article. Clinical Trial.
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. Byers LA, et al. Among authors: heymach jv. Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22. Clin Cancer Res. 2013. PMID: 23091115 Free PMC article.
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. William WN Jr, et al. Among authors: heymach j. J Thorac Oncol. 2013 Feb;8(2):222-8. doi: 10.1097/JTO.0b013e3182774108. J Thorac Oncol. 2013. PMID: 23287849 Free PMC article.
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR Jr, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Tsao AS, et al. Among authors: heymach j. J Thorac Oncol. 2013 May;8(5):658-61. doi: 10.1097/JTO.0b013e31828d08ae. J Thorac Oncol. 2013. PMID: 23584298 Free PMC article. Clinical Trial.
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Wheler J, et al. Among authors: heymach j. Oncotarget. 2013 May;4(5):772-84. doi: 10.18632/oncotarget.1028. Oncotarget. 2013. PMID: 23800712 Free PMC article. Clinical Trial.
515 results